Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-tpknm Total loading time: 0 Render date: 2025-05-01T07:06:17.585Z Has data issue: false hasContentIssue false

8 - Assessment of Tumor Response on Magnetic Resonance Imaging after Locoregional Therapy

from PART II - PRINCIPLES OF IMAGE-GUIDED THERAPIES

Published online by Cambridge University Press:  18 May 2010

By
Manon Buijs ,
Josephina A. Vossen ,
Jean-Francois H. Geschwind  and
Ihab R. Kamel
Edited by
Jean-François H. Geschwind  and
Michael C. Soulen
Manon Buijs
Affiliation:
Postdoctoral Research Fellow, Interventional Radiology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Josephina A. Vossen
Affiliation:
Postdoctoral Research Fellow, Interventional Radiology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Jean-Francois H. Geschwind
Affiliation:
Director of Cardiovascular and Interventional Radiology, Johns Hopkins University School of Medicine
Ihab R. Kamel
Affiliation:
Associate Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD
Jean-François H. Geschwind
Affiliation:
The Johns Hopkins University School of Medicine
Michael C. Soulen
Affiliation:
University of Pennsylvania School of Medicine
Get access

Summary

Assessment of tumor response after locoregional therapy is important in determining treatment success and in guiding future therapy. Magnetic resonance (MR) imaging plays an important role in evaluating treatment response to new therapies directed toward treatment of hepatic tumors. The traditional and accepted criteria to determine tumor response in oncology, namely the Response Evaluation Criteria in Solid Tumors (RECIST), use decrease in tumor size as an indicator of successful therapy. However, because of the lack of size change early after treatment, the European Association for the Study of the Liver (EASL) criteria were introduced and are based on lack of contrast enhancement after therapy as an indicator of favorable response. A more recent evaluation method is the apparent diffusion coefficient (ADC), measured by diffusion-weighted MR imaging. Diffusion-weighted MR imaging and ADC values map the thermally induced motion of water molecules in tissues and thereby are able to provide insight into tumor microstructure. In this chapter, we discuss the role of MR imaging in assessing treatment response after various locoregional therapies. We describe the role of tumor size (as recommended by RECIST) and enhancement (as suggested by EASL) as well as ADC mapping. We also discuss the MR imaging findings after radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and radioembolization.

Although surgical resection and liver transplantation offer the only chance for cure in patients with hepatic malignancies, unfortunately, tumors in most patients are found to be unresectable at time of presentation, leaving palliative therapy as the only option.

Type
Chapter
Information
Interventional Oncology
Principles and Practice
 , pp. 86 - 98
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Dodd, G D 3rd. Minimally invasive treatment of malignant hepatic tumors: At the threshold of a major breakthrough. Radiographics 2000; 20(1): 9–27.CrossRefGoogle ScholarPubMed
Goldberg, S N and Ahmed, M. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35(5 Suppl 2): S115–129.CrossRefGoogle ScholarPubMed
Bartolozzi, C. Hepatocellular carcinoma: CT and MR features after transcatheter arterial embolization and percutaneous ethanol injection. Radiology 1994; 191(1): 123–128.CrossRefGoogle Scholar
Lencioni, R, Caramella, D and Bartolozzi, C. Hepatocellular carcinoma: Use of color Doppler US to evaluate response to treatment with percutaneous ethanol injection. Radiology 1995; 194(1): 113–118.CrossRefGoogle ScholarPubMed
Miller, A B. Reporting results of cancer treatment. Cancer 1981; 47(1): 207–214.3.0.CO;2-6>CrossRefGoogle ScholarPubMed
Therasse, P. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205–216.CrossRefGoogle ScholarPubMed
Jaffe, C C. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006; 24(20): 3245–3251.CrossRefGoogle ScholarPubMed
Kamel, I R and Bluemke, D A. Magnetic resonance imaging of the liver: assessing response to treatment. Top Magn Reson Imaging 2002; 13(3): 191–200.CrossRefGoogle ScholarPubMed
Bruix, J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35(3): 421–430.CrossRefGoogle ScholarPubMed
Bruix, J and Sherman, M. Management of hepatocellular carcinoma. Hepatology 2005; 42(5): 1208–1236.CrossRefGoogle ScholarPubMed
Law, M. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 2003; 24(10): 1989–1998.Google ScholarPubMed
Schaefer, P W, Grant, P E and Gonzalez, R G. Diffusion-weighted MR imaging of the brain. Radiology 2000; 217(2): 331–345.CrossRefGoogle Scholar
Elton, M. Forensic psychiatrists must be more in agreement on the evaluation of juvenile delinquents. Lakartidningen 1991; 88(34): 2668.Google ScholarPubMed
Yeung, D K, Cheung, H S and Tse, G M. Human breast lesions: Characterization with contrast-enhanced in vivo proton MR spectroscopy – initial results. Radiology 2001; 220(1): 40–46.CrossRefGoogle ScholarPubMed
Jagannathan, N R. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001; 84(8): 1016–1022.CrossRefGoogle ScholarPubMed
Longo, R. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993; 28(4): 297–302.CrossRefGoogle ScholarPubMed
Dixon, R M. NMR studies of phospholipid metabolism in hepatic lymphoma. NMR Biomed 1998; 11(7): 370–379.3.0.CO;2-#>CrossRefGoogle ScholarPubMed
Soper, R. Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spectroscopy and a statistical classification strategy. Pathology 2002; 34(5): 417–422.CrossRefGoogle Scholar
Chen, C Y. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: Choline levels and MR diffusion constants – initial experience. Radiology 2006; 239(2): 448–456.CrossRefGoogle Scholar
Moffat, B A. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005; 102(15): 5524–5529.CrossRefGoogle ScholarPubMed
Moffat, B A. The functional diffusion map: An imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006; 8(4): 259–267.CrossRefGoogle ScholarPubMed
Ni, H. Effects of number of diffusion gradient directions on derived diffusion tensor imaging indices in human brain. Am J Neuroradiol 2006;27(8):1776–1781.Google ScholarPubMed
Moseley, M E. Diffusion-weighted MR imaging of anisotropic water diffusion in cat central nervous system. Radiology 1990; 176(2): 439–445.CrossRefGoogle ScholarPubMed
Taouli, B. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003; 226(1): 71–78.CrossRefGoogle ScholarPubMed
Yamada, I. Diffusion coefficients in abdominal organs and hepatic lesions: Evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999; 210(3): 617–623.CrossRefGoogle ScholarPubMed
Lencioni, R, Cioni, D and Bartolozzi, C. Percutaneous radiofrequency thermal ablation of liver malignancies: Techniques, indications, imaging findings, and clinical results. Abdom Imaging 2001; 26(4): 345–360.CrossRefGoogle ScholarPubMed
Sironi, S. Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up. Am J Roentgenol 1999; 173(5): 1225–1229.CrossRefGoogle ScholarPubMed
Buscarini, L. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: Long-term results. Eur Radiol 2001; 11(6): 914–921.CrossRefGoogle ScholarPubMed
Livraghi, T. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: The “test-of-time approach.” Cancer 2003; 97(12): 3027–3035.CrossRefGoogle ScholarPubMed
Goldberg, S N. Tissue ablation with radiofrequency using multiprobe arrays. Acad Radiol 1995; 2(8): 670–674.Google ScholarPubMed
Goldberg, S N. Percutaneous radiofrequency tissue ablation: Does perfusion-mediated tissue cooling limit coagulation necrosis?J Vasc Interv Radiol 1998; 9(1 Pt 1): 101–111.CrossRefGoogle ScholarPubMed
Curley, S A. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004; 239(4): 450–458.CrossRefGoogle ScholarPubMed
Horkan, C. Radiofrequency ablation: Effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model. J Vasc Interv Radiol 2004; 15(3): 269–274.CrossRefGoogle Scholar
Livraghi, T. Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210(3): 655–661.CrossRefGoogle ScholarPubMed
Bartolozzi, C. Assessment of therapeutic effect of liver tumor ablation procedures. Hepatogastroenterology 2001; 48(38): 352–358.Google ScholarPubMed
Rossi, S. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. Am J Roentgenol 1998; 170(4): 1015–1022.CrossRefGoogle ScholarPubMed
Shibata, T. Small hepatocellular carcinoma: Comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002; 223(2): 331–337.CrossRefGoogle ScholarPubMed
Curley, S A. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: Results in 123 patients. Ann Surg 1999; 230(1): 1–8.CrossRefGoogle ScholarPubMed
Bergsland, E K and Venook, A P. Hepatocellular carcinoma. Curr Opin Oncol 2000; 12(4): 357–361.CrossRefGoogle ScholarPubMed
Geschwind, J F. Novel therapy for liver cancer: Direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002; 62(14): 3909–3913.Google ScholarPubMed
Okuda, K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56(4): 918–928.Google Scholar
Lee, H S. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: A prospective cohort study. J Clin Oncol 2002; 20(22): 4459–4465.CrossRefGoogle Scholar
Stefanini, G F. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma: An Italian experience. Cancer 1995; 75(10): 2427–2434.Google ScholarPubMed
Yoshioka, H. MR imaging of the liver before and after transcatheter hepatic chemo-embolization for hepatocellular carcinoma. Acta Radiol 1990; 31(1): 63–67.CrossRefGoogle ScholarPubMed
Lou, C Y. Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98. World J Gastroenterol 2004; 10(10): 1462–1465.CrossRefGoogle ScholarPubMed
Kamel, I R. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 2006; 17(3): 505–512.CrossRefGoogle ScholarPubMed
Parkin, D M. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94(2): 153–156.CrossRefGoogle ScholarPubMed
Lin, D Y. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma – a randomized controlled trial. Gastroenterology 1988; 94(2): 453–456.CrossRefGoogle ScholarPubMed
Pelletier, G. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11(2): 181–184.CrossRefGoogle ScholarPubMed
Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332(19): 1256–1261.CrossRef
Bruix, J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatology 1998; 27(6): 1578–1583.CrossRefGoogle Scholar
Santis, M. Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization. Eur Radiol 1997; 7(1): 10–16.CrossRefGoogle ScholarPubMed
Ito, K. Therapeutic efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma: MRI and pathology. J Comput Assist Tomogr 1995; 19(2): 198–203.CrossRefGoogle ScholarPubMed
Burger, I. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: Initial experience in a single institution. J Vasc Interv Radiol 2005; 16(3): 353–361.CrossRefGoogle Scholar
Naggert, J K. Genomic analysis of the C57BL/Ks mouse strain. Mamm Genome 1995; 6(2): 131–133.CrossRefGoogle ScholarPubMed
Vilgrain, V. Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr 1997; 21(1): 59–65.CrossRefGoogle ScholarPubMed
Jemal, A. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2): 106–130.CrossRefGoogle ScholarPubMed
Carty, N J. Patterns of clinical metastasis in breast cancer: An analysis of 100 patients. Eur J Surg Oncol 1995; 21(6): 607–608.CrossRefGoogle ScholarPubMed
Li, X P. Treatment for liver metastases from breast cancer: Results and prognostic factors. World J Gastroenterol 2005; 11(24): 3782–3787.CrossRefGoogle ScholarPubMed
Moertel, C G. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5(10): 1502–1522.CrossRefGoogle ScholarPubMed
Lepage, C. Incidence and management of malignant digestive endocrine tumours in a well-defined French population. Gut 2004; 53(4): 549–553.CrossRefGoogle Scholar
Modlin, I M and Sandor, A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79(4): 813–829.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
Norton, J A. S urgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol 2005; 19(4): 577–583.CrossRefGoogle Scholar
Tomassetti, P. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005; 16(11): 1806–1810.CrossRefGoogle ScholarPubMed
Norheim, I. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987; 206(2): 115–125.CrossRefGoogle Scholar
Schnirer, II, Yao, J C and Ajani, J A. Carcinoid – a comprehensive review. Acta Oncol 2003; 42(7): 672–692.CrossRefGoogle ScholarPubMed
Gupta, S. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD. Anderson experience. Cancer J 2003; 9(4): 261–267.CrossRefGoogle Scholar
Roche, A. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13(1): 136–140.Google ScholarPubMed
Eriksson, B K. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83(11): 2293–2301.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
Gupta, S. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival. Cancer 2005; 104(8): 1590–1602.CrossRefGoogle Scholar
Geschwind, J F. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1): S194–205.CrossRefGoogle ScholarPubMed
Andrews, J C. Hepatic radioembolization with yttrium-90 containing glass microspheres: Preliminary results and clinical follow-up. J Nucl Med 1994; 35(10): 1637–1644.Google ScholarPubMed
Sarfaraz, M. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Med Phys 2003; 30(2): 199–203.CrossRefGoogle ScholarPubMed
Buscombe, J R and Padhy, A. Treatment of hepatocellular carcinoma: A pivotal role for nuclear medicine?Nucl Med Commun 2001; 22(2): 119–120.CrossRefGoogle ScholarPubMed
Deng, J. Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 2006; 17(7): 1195–1200.CrossRefGoogle ScholarPubMed
Kamel, I R. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18(1 Pt 1): 49–56.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×